TARS
Tarsus Pharmaceuticals Inc
NASDAQ: TARS · HEALTHCARE · BIOTECHNOLOGY
$60.67
-2.29% today
Updated 2026-04-29
Market cap
$2.61B
P/E ratio
—
P/S ratio
5.78x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$39 – $85
Volume
0.6M
Tarsus Pharmaceuticals Inc (TARS) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-38.2%
Last 4 quarters
Revenue YoY growth
+128.4%
Most recent quarter
EPS YoY growth
+66.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+5.6%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+16.5%
2025-08-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-16 | $-0.20 | -139.2% | $67.96 | $69.79 | +2.7% |
| 2025-11-04 | $-0.30 | +14.3% | $69.79 | $68.20 | -2.3% |
| 2025-08-06 | $-0.48 | -26.3% | $41.15 | $47.95 | +16.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.08 | $-0.20 | -139.2% | $151.67M | +128.4% |
| 2025-09-30 | $-0.35 | $-0.30 | +14.3% | $118.70M | +146.7% |
| 2025-06-30 | $-0.38 | $-0.48 | -26.3% | $102.66M | +151.5% |
| 2025-03-31 | $-0.63 | $-0.64 | -1.6% | $78.33M | +183.7% |
| 2024-12-31 | $-0.82 | $-0.60 | +26.4% | $66.41M | +407.9% |
| 2024-09-30 | $-0.94 | $-0.61 | +35.1% | $48.12M | +2471.8% |
| 2024-06-30 | $-0.92 | $-0.88 | +4.3% | $40.81M | +167.2% |
| 2024-03-31 | $-1.20 | $-1.01 | +15.8% | $27.61M | — |
| 2023-12-31 | $-1.36 | $-1.31 | +3.7% | $13.08M | — |
| 2023-09-30 | $-1.37 | $-1.28 | +6.6% | $1.87M | — |
| 2023-06-30 | $-1.08 | $-1.17 | -8.3% | $15.28M | — |
Frequently asked questions
Has Tarsus Pharmaceuticals Inc beaten earnings estimates?
Tarsus Pharmaceuticals Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -38.2% over the last 4 quarters.
How does TARS stock react to earnings?
TARS stock has moved an average of +5.6% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Tarsus Pharmaceuticals Inc's revenue growth rate?
Tarsus Pharmaceuticals Inc reported year-over-year revenue growth of +128.4% in its most recent quarter, with EPS growing +66.7% year-over-year.